Commission Report Highlights the Potential of Personalised Medicine

The European Commission has published a report which takes stock of the progress made in the field of personalised medicine and the opportunities and challenges associated with its implementation in a healthcare setting. The report focuses on three main areas: 1) the potential for, and issues with, the use of '-omics' technologies in personalised medicine, and the related EU research funding, 2) recent developments in EU legislation for placing medicinal products and devices on the market, and 3) factors affecting the uptake of personalised medicine in health care systems.

The report concludes that personalised medicine has the potential to offer new treatment opportunities for the benefit of patients, including better targeted treatment, avoiding medical errors and reducing adverse reactions to medicines.

Personalised Medicine should be seen as an evolution of medicine, rather than a revolution, and the report recognises the challenges (e.g. in research) associated with its successful entry in healthcare systems. The European Commission will continue to monitor the developments of personalised medicine in the coming years and maintain a fruitful dialogue with stakeholders.

What is personalised medicine?
Although no official definition of personalised medicine exists, it can best be explained as a medical approach which is tailored to the patient or a group of pati! ents - for prevention, prediction and treatment. In other words, it moves away from the common "one size fits all" medical model.

How does the EU support personalised medicine?
Since 2007 the EU has committed over €1 billion of health research funding underpinning the development of personalised medicine through its Seventh Framework Program for Research and Technological Innovation. Going forward, funding under Horizon 2020, the EU's new framework program to be launched at the end of this year, will continue to support this field.

A constructive legal framework has also contributed to the development of personalised medicine. The regulatory framework for pharmaceuticals offers a number of tools and procedures to ensure that medicines placed on the market are of high quality, safety and efficacy. These tools, complemented by scientific guidelines and expert evaluation, have already worked well for innovative products including therapies relevant to personalised medicine.

The ongoing revisions of important pieces of legislation address certain challenges identified in the development of these therapies. The revision of the medical devices legislation will strengthen the legal framework of in vitro diagnostics and introduce a better consultation process for companion diagnostics to assess patient eligibility for treatment with a specific medicinal product. The revision of the Clinical Trials Directive is expected to simplify the conduct of clinical trials and consequently facilitate research in therapies using personalised medicine.

Finally, EU-level cooperation on Health Technology Assessment can help Member States assess the value of using personalised medicine in their health systems, i.e. judge whether their benefits will offset their costs through efficiency gains.

Download: Use of '-omics' technologies in the development of personalised medicine (.pdf, 258 KB).

Download from eHealthNews.eu Portal's mirror: Use of '-omics' technologies in the development of personalised medicine (.pdf, 258 KB).

Most Popular Now

Collective Intelligence can Help Reduce …

An estimated 250,000 people die from preventable medical errors in the U.S. each year. Many of these errors originate during the diagnostic process. A powerful way to increase diagnostic accuracy...

Software Created from 'Building Blo…

New 'building-block' approaches to the creation of digital tools which include data and artificial intelligence (AI) could play a key role in improving the running of hospital wards and disease...

How could Technology Better Support Pati…

The NHS exists to serve patients. But more could be done to make their experience a key focus when it comes to technology adoption, senior NHS delegates told a recent...

"Showtime" for Digital Health …

13 - 16 November 2023, Düsseldorf, Germany. A hundred start-ups and more than 120 high-calibre professional speakers: These are just the "naked" facts which this year's MEDICA CONNECTED HEALTHCARE FORUM will...

Artificial Intelligence: Unexpected Resu…

Artificial intelligence (AI) is on the rise. Until now, AI applications generally have "black box" character: How AI arrives at its results remains hidden. Prof. Dr. Jürgen Bajorath, a cheminformatics...

Philips Program Developing AI-Powered Ul…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received a second round of funding from the Bill & Melinda Gates Foundation to...

CGM Continues to Drive Digitization in H…

CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, successfully progressed the digitization in healthcare during the first three quarters in 2023. CGM supports physicians...

Wolverhampton's New 10-Year EPR Dea…

The Royal Wolverhampton NHS Trust (RWT) has just signed a 10-year contract with System C for an integrated electronic patient record (EPR) system, which will replace the trust's in-house built...

Printed Robots with Bones, Ligaments, an…

3D printing is advancing rapidly, and the range of materials that can be used has expanded considerably. While the technology was previously limited to fast-curing plastics, it has now been...

Orchestrating the New World of AI in Hea…

Orion Health's UK and Ireland Customer Conference 2023 focused on the future potential and immediate, practical application of AI to healthcare - and gave delegates a first look at the...

Researchers Take New AI Approach to Anal…

Researchers at Karolinska Institutet and SciLifeLab in Sweden have combined artificial intelligence (AI) techniques used in satellite imaging and community ecology to interpret large amounts of data from tumour tissue...

AI identifies Non-Smokers at High Risk f…

Using a routine chest X-ray image, an artificial intelligence (AI) tool can identify non-smokers who are at high risk for lung cancer, according to a study being presented next week...